Chang v. Neumora Therapeutics, Inc. et al

  1. March 13, 2026

    Neuropsych Drugmaker Wants Out Of Investors' IPO Data Suit

    Neuropsychiatric drugmaker Neumora Therapeutics Inc. seeks to shed investor claims it mischaracterized certain clinical study data ahead of its September 2023 initial public offering, arguing that the trading price decline cited in the complaint was tied to results from a different study that occurred after the IPO.

  2. February 10, 2025

    Pharma Co. Misled Investors On Depression Drug, Suit Says

    Brain disease drugmaker Neumora Therapeutics Inc. has been hit with a proposed shareholder class action alleging that the company and its initial public offering underwriters failed to disclose prior to the $250 million IPO that Neumora's clinical trial for a depression treatment was very unlikely to yield promising results.